![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1339173
¾ÐŸ¸Ó ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ ¹× »ê¾÷ ºÐ¼® º¸°í¼ : À¯Çüº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° µ¿Çâ(2023-2032³â)Aptamers Market Share, Size, Trends, Industry Analysis Report, By Type (Nucleic Acid, Peptide); By Application (Diagnostics, Therapeutics, Research & Developments, Others); By Region, And Segment Forecasts, 2023 - 2032 |
Polaris Market ResearchÀÇ ÃֽŠ¿¬±¸¿¡ µû¸£¸é, ¼¼°è ¾ÐŸ¸Ó ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 163¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
¾ÐŸ¸ÓÀÇ ´ÙÀç´Ù´ÉÇÔ°ú ÇコÄɾî, »ý¸í°øÇÐ, Áø´Ü µî ´Ù¾çÇÑ »ê¾÷¿¡¼ ÀáÀçÀûÀÎ ÀÀ¿ë °¡´É¼ºÀÌ ¸¹Àº ±â¾÷µéÀÇ °ü½ÉÀ» ²ø°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ Ÿ°ÙÀ» À§ÇÑ ¸ÂÃãÇü ¾ÐŸ¸Ó°¡ °¡´ÉÇØÁö¸é¼ ¾ÐŸ¸ÓÀÇ ¿ëµµ´Â ÀüÅëÀûÀÎ ¿¬±¸ ¹× Áø´Ü ºÐ¾ß ¿Ü¿¡µµ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ä¡·áÁ¦¿Í ¹ÙÀÌ¿À¼¾¼ µî ¾ÐŸ¸Ó¸¦ ±â¹ÝÀ¸·Î ÇÑ ½ÅÁ¦Ç°ÀÌ °³¹ßµÇ¾î ¾ÐŸ¸Ó ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
SELEX ±â¼úÀº SARS-CoV-2 ¹× Äڷγª19¿Í °ü·ÃµÈ ƯÁ¤ ¹ÙÀÌ¿À¸¶Ä¿¿¡ °áÇÕÇÒ ¼ö ÀÖ´Â ¾ÐŸ¸Ó¸¦ °³¹ßÇÏ¿© Áø´Ü ŰƮ ¹× ºÐ¼®¹ýÀ» °³¹ßÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾ÐŸ¸Ó ±â¹Ý Áø´Ü µµ±¸´Â ¹ÙÀÌ·¯½º ¹× °ü·Ã ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °ËÃâ¿¡ ÀÖ¾î ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Á¦°øÇÏ¿© Áúº´ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ ÀÌ·¯ÇÑ Áø´Ü ŰƮ ¹× ºÐ¼® ½ÃÀå µµÀÔÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
2021³â 12¿ù, Achiko AGÀÇ Äڷγª19 Áø´ÜŰƮ Aptamex°¡ Àεµ³×½Ã¾Æ º¸°ÇºÎÀÇ ½ÂÀÎÀ» ¹Þ¾ÒÀ¸¸ç, Aptamex´Â DNA ¾ÐŸ¸Ó ±â¼ú·Î °³¹ßµÈ 2¼¼´ë Áø´ÜŰƮ·Î ºñ¿ë È¿À²ÀûÀ̰í ÈÇÐÀûÀ¸·Î ÇÕ¼ºµÈ ÀǾàǰ Áø´Ü ŰƮÀÔ´Ï´Ù.
½ÃÀå ¼ºÀåÀº ¹Ì±¹ FDA, ij³ª´Ù º¸°ÇºÎ, EMA, COFEPRIS, MHRA, CDSCO µî ´Ù¾çÇÑ ±ÔÁ¦ ±â°üÀÌ ÀÌ ºÐ¾ßÀÇ ¿¬±¸°³¹ßÀ» Áö¿øÇϱâ À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃëÇÔÀ¸·Î½á ´õ¿í µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 3¿ù ¹Ì±¹ FDA´Â AMD¿¡ À̾î Áö¸®Àû À§ÃàÁõ(GA) ȯÀÚ¸¦ À§ÇÑ Ä¡·áÁ¦·Î IVERIC BioÀÇ Áö¹«¶ó(Zimura)¸¦ ÆÐ½ºÆ®Æ®·¢(Fast Track) ÁöÁ¤Çß½À´Ï´Ù. Áö¹«¶ó(Zimura)´Â Æä±×È RNA ¾ÐŸ¸Ó(pegylated RNA aptamer)¸¦ ÇÕ¼ºÇÏ¿© À¯¸®Ã¼°³» ÁÖ»ç·Î Åõ¿©Çϸç, AMD ¹ßº´ÀÇ ¿øÀÎÀ¸·Î ¾Ë·ÁÁø C5 ÀÎÀÚ¸¦ ¾ïÁ¦ÇÏ´Â ¹æ½ÄÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù.
Áø´Ü, Ä¡·á, ¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÇÙ»ê ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡ÇÕ´Ï´Ù.
¿¬±¸°³¹ß ºÐ¾ß´Â ¾ÐŸ¸Ó Á¦Á¶±â¾÷¿¡ ´ëÇÑ ³ôÀº °ü½É°ú Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·ÂÀ¸·Î ½ÃÀå Á¡À¯À² 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.
Áø´Ü ºÐ¾ß´Â Áúº´ÀÇ Á¶±â Áø´ÜÀ» À§ÇÑ ¾ÐŸ¸Ó ±â¹Ý Áø´Ü ŰƮ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó °¡Àå ºü¸¥ ¼ºÀå·üÀ» ±â·ÏÇß½À´Ï´Ù.
ºÏ¹Ì´Â ¾ÐŸ¸Ó °³¹ß¿¡ Á¾»çÇÏ´Â ±â¾÷ÀÇ Á¸Àç¿Í °úÇÐÀû Çõ½ÅÀ» À§ÇÑ °·ÂÇÑ »êÇÐÇù·ÂÀ¸·Î ÀÎÇØ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº ´ë±Ô¸ð ȯÀÚ Ç®ÀÇ Á¸Àç, °Å´ëÇÑ ¹Ì°³Ã´ Àα¸, ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ¿ìÈ£ÀûÀÎ Á¤Ã¥À¸·Î ÀÎÇØ ³ôÀº ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global aptamers market size is expected to reach USD 16.33 billion by 2032, according to a new study by Polaris Market Research. The report "Aptamers Market Share, Size, Trends, Industry Analysis Report, By Type (Nucleic Acid, and Peptide); By Application (Diagnostics, Therapeutics, Research & Developments, and Others); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Versatility of aptamers and their potential applications in various industries such as healthcare, biotechnology, and diagnostics have attracted the attention of many companies. Moreover, the availability of customized aptamers for specific targets has expanded the applications of aptamers beyond their traditional use in research and diagnostics. This has led to the development of new aptamer-based products, including therapeutics and biosensors, which are expected to further drive the growth of the aptamers market.
The SELEX technology has been used to develop aptamers that can bind to specific biomarkers related to SARS-CoV-2 and COVID-19, allowing for the development of diagnostic kits and assays. These aptamer-based diagnostic tools can provide high sensitivity and specificity in detecting the virus and related biomarkers, which can aid in disease diagnosis and monitoring. As a result, the introduction of such diagnostic kits and assays in the market is expected to drive the growth of the market.
In December 2021, Achiko AG's Aptamex, a COVID-19 diagnostic kit, received approval from the health ministry of Indonesia. Aptamex is a 2nd generation kit developed using DNA aptamer technology, which is cost-effective, chemically synthesized, diagnostic kit in the pharmaceuticals.
Market growth is further supported by various regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, & CDSCO, which have taken initiatives to support the research and development in this field. For example, in March 2020, the U.S. FDA granted Fast Track designation to IVERIC Bio's Zimura for the treatment of patients with geographic atrophy (GA) secondary to AMD. It is a pegylated RNA aptamer, which is synthesized & administered by the intra-vitreal injection. It works by the inhibition of factor C5, considered responsible for onset of AMD.
Nucleic acid segment dominated the market, owing to rapid development in the diagnostics, therapeutics, and advancements in the biomarker discovery
R&D segment accounted for the larger market share, as there is a strong interest in aptamer manufacturing companies, and favorable government initiatives
Diagnostic segment recorded fastest growth rate, owing to rising need for aptamer based diagnostic kits for the early disease diagnosis
North America garnered the largest share, owing to the presence of companies engaged in the development of aptamers, and strong industry academia collaboration for scientific breakthroughs
Asia Pacific is projected to register a higher growth rate, owing to the presence of large patient pool, huge untapped population, and favorable government policies for research.
The global players include: Base Pair Biotechnologies, SomaLogic, Aptadel Therapeutics, Aptamer Group, Noxxon Pharma, Aptagen, TriLink Biotechnologies, Altermune, Vivonics, and AM Biotechnologies.
Polaris Market Research has segmented the aptamers market report based on type, application, and region: